Latest News and Press Releases

Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease

Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026

Agios announces first quarter 2026 financial results and provides business update.

Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease

PYRUKYND (mitapivat) approved for adults with thalassemia in the United Arab Emirates

Agios today announced its 2026 strategic priorities and key milestones anticipated during the year.

Agios today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

Agios today announced that the U.S. FDA has approved AQVESME™ (mitapivat), an oral pyruvate kinase (PK) activator, for thalassemia

Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia

Agios today announced topline results from the 52-week double-blind period of the global RISE UP Phase 3 trial